Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
J Alzheimers Dis ; 58(4): 1189-1199, 2017.
Article in English | MEDLINE | ID: mdl-28527220

ABSTRACT

BACKGROUND: The interrelationships between omega-3 fatty acids status, brain perfusion, and cognition are not well understood. OBJECTIVE: To evaluate if SPECT brain imaging of cerebral perfusion and cognition varies as a function of omega-3 fatty acid levels. METHODS: A random sample of 166 study participants was drawn from a psychiatric referral clinical for which erythrocyte quantification of omega-3 eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) (the Omega-3 Index) was available. Quantitative brain SPECT was done on 128 regions based on a standard anatomical Atlas. Persons with erythrocyte EPA+DHA concentrations were dichotomized based on membership in top 50th percentile versus bottom 50th percentile categories. Two-sample t-tests were done to identify statistically significant differences in perfusion between the percentile groups. Partial correlations were modeled between EPA+DHA concentration and SPECT regions. Neurocognitive status was assessed using computerized testing (WebNeuro) and was separately correlated to cerebral perfusion on brain SPECT imaging and omega-3 EPA+DHA levels. RESULTS: Partial correlation analyses showed statistically significant relationships between higher omega-3 levels and cerebral perfusion were in the right parahippocampal gyrus (r = 0.20, p = 0.03), right precuneus (r = 0.20, p = 0.03), and vermis subregion 6 (p = 0.21, p = 0.03). Omega-3 Index levels separately correlated to the feeling subsection of the WebNeuro (r = 0.25, p = 0.01). CONCLUSION: Quantitative omega-3 EPA+DHA erythrocyte concentrations are independently correlated with brain perfusion on SPECT imaging and neurocognitive tests. These results have implications for the role of omega-3 fatty acids toward contributing to cognitive reserve.


Subject(s)
Brain/diagnostic imaging , Brain/metabolism , Cerebrovascular Circulation/physiology , Docosahexaenoic Acids/metabolism , Eicosapentaenoic Acid/metabolism , Erythrocytes/metabolism , Adult , Female , Humans , Male , Mental Status Schedule , Middle Aged , Tomography, Emission-Computed, Single-Photon
2.
Altern Med Rev ; 15(3): 199-222, 2010 Sep.
Article in English | MEDLINE | ID: mdl-21155624

ABSTRACT

Vitamins D and K are lipid-phase nutrients that are pleiotropic - endowed with versatile homeostatic capacities at the organ, tissue, and cellular levels. Their metabolic and physiologic roles overlap considerably, as evidenced in the bone and cardiovascular systems. Vitamin D3 (cholecalciferol, D3) is the prehormone for the vitamin D endocrine system. Vitamin D3 undergoes initial enzymatic conversion to 25-hydroxyvitamin D (25D, calcidiol), then to the seco-steroid hormone 1alpha, 25-dihydroxyvitamin D (1,25D, calcitriol). Beyond its endocrine roles in calcium homeostasis, 1,25D likely has autocrine, paracrine, and intracrine effects. At least 17 tissues likely synthesize 1,25D, and 35 carry the vitamin D receptor (VDR). Vitamin D functional deficiency is widespread in human populations. Vitamin K1 (phylloquinone) is more abundant in foods but less bioactive than the vitamin K2 menaquinones (especially MK-4, menatetrenone). Menadione (vitamin K3) has minimal K activity. Vitamin K compounds undergo oxidation-reduction cycling within the endoplasmic reticulum membrane, donating electrons to activate specific proteins via enzymatic gamma-carboxylation of glutamate groups before being enzymatically re-reduced. Warfarin inhibits this vitamin K reduction, necessitating K supplementation during anticoagulation therapy. Along with coagulation factors (II, VII, IX, X, and prothrombin), protein C and protein S, osteocalcin (OC), matrix Gla protein (MGP), periostin, Gas6, and other vitamin K-dependent (VKD) proteins support calcium homeostasis, facilitate bone mineralization, inhibit vessel wall calcification, support endothelial integrity, are involved in cell growth control and tissue renewal, and have numerous other effects. This review updates vitamin D and K skeletal and cardiovascular benefits and evidence for their synergy of action.


Subject(s)
Bone Diseases/prevention & control , Calcification, Physiologic/drug effects , Cardiovascular Diseases/prevention & control , Cholecalciferol/pharmacology , Vitamin K/pharmacology , Bone Density/drug effects , Bone and Bones/drug effects , Cardiovascular System/drug effects , Cholecalciferol/administration & dosage , Fractures, Bone/prevention & control , Humans , Nutritional Physiological Phenomena , Osteoblasts/drug effects , Osteocytes/drug effects , Vitamin D Deficiency/prevention & control , Vitamin K/administration & dosage , Vitamin K 1/pharmacology , Vitamin K 2/pharmacology , Vitamin K 3/pharmacology , Vitamin K Deficiency/prevention & control
3.
Altern Med Rev ; 14(3): 226-46, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19803548

ABSTRACT

Plant-derived polyphenols are increasingly receiving attention as dietary supplements for the homeostatic management of inflammation, to support detoxication, and for anticancer, weight loss, and other benefits. Their pro-homeostatic effects on genes, transcription factors, enzymes, and cell signaling pathways are being intensively explored, but the poor bioavailability of some polyphenols likely contributes to poor clinical trial outcomes. This review covers four polyphenol preparations with poor bioavailability and their complexation into phytosomes to bypass this problem. Silybin and the other silymarin flavonolignans from milk thistle conserve tissue glutathione, are liver-protective, and have anticancer potential. Curcumin and its related diphenolic curcuminoids have potent antioxidant, anti-inflammatory, and anti-carcinogenic properties. The green tea flavan-3-ol catechins have antioxidant, anti-inflammatory, cardio- and neuro-protective effects, and anti-carcinogenic benefits, with fat oxidation effects coupled to weight loss. The complex grape seed proanthocyanidin mix (including catechin and epicatechin monomers and oligomers) counters oxidative stress and protects the circulatory system. For each of these preparations, conversion into phytosomes has improved efficacy without compromising safety. The phytosome technology creates intermolecular bonding between individual polyphenol molecules and one or more molecules of the phospholipid, phosphatidylcholine (PC). Molecular imaging suggests that PC molecule(s) enwrap each polyphenol; upon oral intake the amphipathic PC molecules likely usher the polyphenol through the intestinal epithelial cell outer membrane, subsequently accessing the bloodstream. PC itself has proven clinical efficacy that contributes to phytosome in vivo actions. As a molecular delivery vehicle, phytosome technology substantially improves the clinical applicabilities of polyphenols and other poorly absorbed plant medicinals.


Subject(s)
Curcumin/pharmacokinetics , Grape Seed Extract/pharmacokinetics , Phytotherapy/methods , Protective Agents/pharmacokinetics , Silymarin/pharmacokinetics , Tea , Animals , Anti-Inflammatory Agents/pharmacokinetics , Anti-Inflammatory Agents/therapeutic use , Antioxidants/pharmacokinetics , Antioxidants/therapeutic use , Biological Availability , Chemoprevention/methods , Clinical Trials as Topic , Curcumin/therapeutic use , Free Radical Scavengers/pharmacokinetics , Free Radical Scavengers/therapeutic use , Grape Seed Extract/therapeutic use , Humans , Silybum marianum , Oxidative Stress/drug effects , Protective Agents/therapeutic use , Silymarin/therapeutic use
4.
Altern Med Rev ; 14(1): 14-35, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19364191

ABSTRACT

Brain injury from ischemic stroke can be devastating, but full brain restoration is feasible. Time until treatment is critical; rapid rate of injury progression, logistical and personnel constraints on neurological and cardiovascular assessment, limitations of recombinant tissue plasminogen activator (rtPA) for thrombolysis, anticoagulation and antiplatelet interventions, and neuroprotection all affect outcome. Promising acute neuroprotectant measures include albumin, magnesium, and hypothermia. Long-term hyperbaric oxygen therapy (HBOT) is safe and holds great promise. Eicosanoid and cytokine down-regulation by omega-3 nutrients docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) may help quench stroke inflammation. C-reactive protein (CRP), an inflammatory biomarker and stroke-recurrence predictor, responds favorably to krill oil (a phospholipid-DHA/EPA-astaxanthin complex). High homocysteine (Hcy) is a proven predictor of stroke recurrence and responds to folic acid and vitamin B12. Vitamin E may lower recurrence for individuals experiencing high oxidative stress. Citicoline shows promise for acute neuroprotection. Glycerophosphocholine (GPC) is neuroprotective and supports neuroplasticity via nerve growth factor (NGF) receptors. Stem cells have shown promise for neuronal restoration in randomized trials. Endogenous brain stem cells can migrate to an ischemic injury zone; exogenous stem cells once transplanted can migrate (home) to the stroke lesion and provide trophic support for cortical neuroplasticity. The hematopoietic growth factors erythropoietin (EPO) and granulocyte-colony stimulating factor (G-CSF) have shown promise in preliminary trials, with manageable adverse effects. Physical and mental exercises, including constraint-induced movement therapy (CIMT) and interactive learning aids, further support brain restoration following ischemic stroke. Brain plasticity underpins the function-driven brain restoration that can occur following stroke.


Subject(s)
Brain Ischemia/complications , Stroke/therapy , Anticoagulants/therapeutic use , Brain/physiology , Homocysteine/metabolism , Humans , Hyperbaric Oxygenation , Inflammation/physiopathology , Inflammation/prevention & control , Intercellular Signaling Peptides and Proteins/therapeutic use , Neuronal Plasticity/physiology , Neuroprotective Agents/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Recovery of Function , Risk Factors , Secondary Prevention , Stem Cell Transplantation , Stroke/etiology , Stroke/physiopathology , Thrombolytic Therapy/methods , Vasodilator Agents/therapeutic use
5.
Altern Med Rev ; 13(2): 85-115, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18590347

ABSTRACT

Alzheimer's disease, AD, is the most common form of dementia. AD initially targets memory and progressively destroys the mind. The brain atrophies as the neocortex suffers neuronal, synaptic, and dendritic losses, and the hallmark amyloid plaques and neurofibrillary tangles proliferate. Pharmacological management, at best, is palliative and transiently effective, with marked adverse effects. Certain nutrients intrinsic to human biochemistry (orthomolecules) match or exceed pharmacological drug benefits in double-blind, randomized, controlled trials, with superior safety. Early intervention is feasible because its heritability is typically minimal and pathological deterioration is detectable years prior to diagnosis. The syndrome amnestic mild cognitive impairment exhibits AD pathology and to date has frustrated attempts at intervention. The condition age-associated memory impairment is a nonpathological extreme of normal brain aging, but with less severe cognitive impairment than amnestic mild cognitive impairment. Age-associated memory impairment is a feasible target for early intervention against AD, beginning with the modifiable AD risk factors - smoking, hypertension, homocysteine, type 2 diabetes, insulin resistance, and obesity. Stress reduction, avoidance of toxins, and mental and physical exercise are important aspects of prevention. The diet should emphasize omega-3 fatty acids docosahexaenoic acid and eicosapentaenoic acid; flavonoids and other antioxidant nutrients; and B vitamins, especially folate, B6 and B12. Dietary supplementation is best focused on those proven from randomized, controlled trials: the phospholipids phosphatidylserine and glycerophosphocholine, the energy nutrient acetyl-L-carnitine, vitamins C and E, and other antioxidants. A comprehensive integrative strategy initiated early in cognitive decline is the most pragmatic approach to controlling progression to Alzheimer's disease.


Subject(s)
Alzheimer Disease/prevention & control , Cognition Disorders/prevention & control , Memory Disorders/prevention & control , Alzheimer Disease/etiology , Alzheimer Disease/pathology , Amnesia/complications , Amnesia/diagnosis , Amnesia/prevention & control , Cognition Disorders/complications , Cognition Disorders/diagnosis , Dietary Supplements , Disease Progression , Humans , Memory Disorders/complications , Memory Disorders/diagnosis , Risk Factors , Stress, Physiological/prevention & control
6.
Altern Med Rev ; 12(3): 207-27, 2007 Sep.
Article in English | MEDLINE | ID: mdl-18072818

ABSTRACT

The omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are orthomolecular, conditionally essential nutrients that enhance quality of life and lower the risk of premature death. They function exclusively via cell membranes, in which they are anchored by phospholipid molecules. DHA is proven essential to pre- and postnatal brain development, whereas EPA seems more influential on behavior and mood. Both DHA and EPA generate neuroprotective metabolites. In double-blind, randomized, controlled trials, DHA and EPA combinations have been shown to benefit attention deficit/hyperactivity disorder (AD/HD), autism, dyspraxia, dyslexia, and aggression. For the affective disorders, meta-analyses confirm benefits in major depressive disorder (MDD) and bipolar disorder, with promising results in schizophrenia and initial benefit for borderline personality disorder. Accelerated cognitive decline and mild cognitive impairment (MCI) correlate with lowered tissue levels of DHA/EPA, and supplementation has improved cognitive function. Huntington disease has responded to EPA. Omega-3 phospholipid supplements that combine DHA/EPA and phospholipids into the same molecule have shown marked promise in early clinical trials. Phosphatidylserine with DHA/EPA attached (Omega-3 PS) has been shown to alleviate AD/HD symptoms. Krill omega-3 phospholipids, containing mostly phosphatidylcholine (PC) with DHA/EPA attached, markedly outperformed conventional fish oil DHA/EPA triglycerides in double-blind trials for premenstrual syndrome/dysmenorrhea and for normalizing blood lipid profiles. Krill omega-3 phospholipids demonstrated anti-inflammatory activity, lowering C-reactive protein (CRP) levels in a double-blind trial. Utilizing DHA and EPA together with phospholipids and membrane antioxidants to achieve a triple cell membrane synergy may further diversify their currently wide range of clinical applications.


Subject(s)
Affect , Behavior , Cognition , Docosahexaenoic Acids/therapeutic use , Eicosapentaenoic Acid/therapeutic use , Adult , Affect/drug effects , Aggression/drug effects , Animals , Apraxias/diet therapy , Attention Deficit Disorder with Hyperactivity/diet therapy , Autistic Disorder/diet therapy , Behavior/drug effects , Brain/embryology , Brain/growth & development , Child , Cognition/drug effects , Dementia/diet therapy , Dementia/prevention & control , Dysmenorrhea/diet therapy , Eicosapentaenoic Acid/physiology , Female , Humans , Huntington Disease/diet therapy , Infant, Newborn , Inflammation Mediators/physiology , Membrane Lipids/physiology , Mood Disorders/diet therapy , Phospholipids/physiology
7.
Altern Med Rev ; 10(4): 268-93, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16366737

ABSTRACT

Degenerative brain disorders (neurodegeneration) can be frustrating for both conventional and alternative practitioners. A more comprehensive, integrative approach is urgently needed. One emerging focus for intervention is brain energetics. Specifically, mitochondrial insufficiency contributes to the etiopathology of many such disorders. Electron leakages inherent to mitochondrial energetics generate reactive oxygen free radical species that may place the ultimate limit on lifespan. Exogenous toxins, such as mercury and other environmental contaminants, exacerbate mitochondrial electron leakage, hastening their demise and that of their host cells. Studies of the brain in Alzheimer's and other dementias, Down syndrome, stroke, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Friedreich's ataxia, aging, and constitutive disorders demonstrate impairments of the mitochondrial citric acid cycle and oxidative phosphorylation (OXPHOS) enzymes. Imaging or metabolic assays frequently reveal energetic insufficiency and depleted energy reserve in brain tissue in situ. Orthomolecular nutrients involved in mitochondrial metabolism provide clinical benefit. Among these are the essential minerals and the B vitamin group; vitamins E and K; and the antioxidant and energetic cofactors alpha-lipoic acid (ALA), ubiquinone (coenzyme Q10; CoQ10), and nicotinamide adenine dinucleotide, reduced (NADH). Recent advances in the area of stem cells and growth factors encourage optimism regarding brain regeneration. The trophic nutrients acetyl L-carnitine (ALCAR), glycerophosphocholine (GPC), and phosphatidylserine (PS) provide mitochondrial support and conserve growth factor receptors; all three improved cognition in double-blind trials. The omega-3 fatty acid docosahexaenoic acid (DHA) is enzymatically combined with GPC and PS to form membrane phospholipids for nerve cell expansion. Practical recommendations are presented for integrating these safe and well-tolerated orthomolecular nutrients into a comprehensive dietary supplementation program for brain vitality and productive lifespan.


Subject(s)
Dietary Supplements , Mitochondrial Diseases/therapy , Nerve Growth Factor/therapeutic use , Neurodegenerative Diseases/therapy , Stem Cell Transplantation , Aging/physiology , Humans , Mitochondria/physiology , Mitochondrial Diseases/complications , Neurodegenerative Diseases/etiology , Oxidative Stress
8.
Altern Med Rev ; 9(2): 107-35, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15253674

ABSTRACT

Bipolar disorder (BD) is characterized by periods of abnormally elevated mood (mania) that cycle with abnormally lowered mood (depression). Multiple structural, metabolic, and biochemical abnormalities are evident in the brain's cortex, subcortex, and deeper regions. This disorder is highly genetically conditioned but also highly susceptible to environmental stressors: prenatal or perinatal insults, childhood sexual or physical abuse, challenging life events, substance abuse, and other toxic chemical exposures. Its high morbidity, lost productivity, and suicide risk place a great toll on society. Since World War II, BD has been steadily worsening with earlier age of onset, greater intensity of symptoms, and development of drug resistance. Incidence in children is rising and misdiagnosis is common. Disciplined management of the many risk factors is essential, including cognitive psychotherapy and support from family and community. Lithium has been the foundational treatment, followed by valproate and other mood stabilizers, antidepressants, and anticonvulsants. Several single-nutrient and multinutrient supplements have also proven beneficial. Controlled, double-blind trials show multinutrient combinations of vitamins, minerals, orthomolecules, herbals, and the omega-3 fatty acids EPA and DHA to be effective monotherapy. The molecular action of lithium and valproate converge with nutrients on the level of the cell membrane and its molecular signal transduction systems. This emergent, unified rationale presages effective integrative management of bipolar disorder.


Subject(s)
Bipolar Disorder/etiology , Cell Membrane/physiology , Adolescent , Adult , Bipolar Disorder/diet therapy , Bipolar Disorder/drug therapy , Bipolar Disorder/physiopathology , Bipolar Disorder/therapy , Cell Membrane/drug effects , Child , Humans , Nimodipine , Psychotherapy , Psychotropic Drugs/therapeutic use , Signal Transduction/drug effects , Signal Transduction/physiology
10.
Altern Med Rev ; 7(6): 472-99, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12495373

ABSTRACT

Autism and allied autistic spectrum disorders (ASD) present myriad behavioral, clinical, and biochemical abnormalities. Parental participation, advanced testing protocols, and eclectic treatment strategies have driven progress toward cure. Behavioral modification and structured education are beneficial but insufficient. Dietary restrictions, including removal of milk and other casein dairy products, wheat and other gluten sources, sugar, chocolate, preservatives, and food coloring are beneficial and prerequisite to benefit from other interventions. Individualized IgG or IgE testing can identify other troublesome foods but not non-immune mediated food sensitivities. Gastrointestinal improvement rests on controlling Candida and other parasites, and using probiotic bacteria and nutrients to correct dysbiosis and decrease gut permeability. Detoxification of mercury and other heavy metals by DMSA/DMPS chelation can have marked benefit. Documented sulfoxidation-sulfation inadequacies call for sulfur-sulfhydryl repletion and other liver p450 support. Many nutrient supplements are beneficial and well tolerated, including dimethylglycine (DMG) and a combination of pyridoxine (vitamin B6) and magnesium, both of which benefit roughly half of ASD cases. Vitamins A, B3, C, and folic acid; the minerals calcium and zinc; cod liver oil; and digestive enzymes, all offer benefit. Secretin, a triggering factor for digestion, is presently under investigation. Immune therapies (pentoxifyllin, intravenous immunoglobulin, transfer factor, and colostrum) benefit selected cases. Long-chain omega-3 fatty acids offer great promise. Current pharmaceuticals fail to benefit the primary symptoms and can have marked adverse effects. Individualized, in-depth clinical and laboratory assessments and integrative parent-physician-scientist cooperation are the keys to successful ASD management.


Subject(s)
Autistic Disorder/therapy , Amino Acids/metabolism , Autistic Disorder/drug therapy , Autistic Disorder/etiology , Blood Coagulation Disorders/therapy , Chelating Agents/therapeutic use , Dietary Supplements , Disease Susceptibility/diagnosis , Feeding Behavior , Food Hypersensitivity/complications , Gastrointestinal Agents/therapeutic use , Gastrointestinal Diseases/complications , Gastrointestinal Diseases/therapy , Humans , Mercury Poisoning/therapy , Parenting , Peptides/metabolism , Secretin/therapeutic use
11.
Altern Med Rev ; 7(4): 292-316, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12197782

ABSTRACT

Autism, archetype of the autistic spectrum disorders (ASD), is a neurodevelopmental disorder characterized by socially aloof behavior and impairment of language and social interaction. Its prevalence has surged in recent years. Advanced functional brain imaging has confirmed pervasive neurologic involvement. Parent involvement in autism management has accelerated understanding and treatment. Often accompanied by epilepsy, cognitive deficits, or other neurologic impairment, autism manifests in the first three years of life and persists into adulthood. Its etiopathology is poorly defined but likely multifactorial with heritability playing a major role. Prenatal toxic exposures (teratogens) are consistent with autism spectrum symptomatology. Frequent vaccinations with live virus and toxic mercurial content (thimerosal) are a plausible etiologic factor. Autistic children frequently have abnormalities of sulfoxidation and sulfation that compromise liver detoxification, which may contribute to the high body burden of xenobiotics frequently found. Frequent copper-zinc imbalance implies metallothionein impairment that could compound the negative impact of sulfur metabolism impairments on detoxification and on intestinal lining integrity. Intestinal hyperpermeability manifests in autistic children as dysbiosis, food intolerances, and exorphin (opioid) intoxication, most frequently from casein and gluten. Immune system abnormalities encompass derangement of antibody production, skewing of T cell subsets, aberrant cytokine profiles, and other impairments consistent with chronic inflammation and autoimmunity. Coagulation abnormalities have been reported. Part 2 of this review will attempt to consolidate progress in integrative management of autism, aimed at improving independence and lifespan for people with the disorder.


Subject(s)
Autistic Disorder , Child Development , Health Knowledge, Attitudes, Practice , Autistic Disorder/diagnosis , Autistic Disorder/etiology , Autistic Disorder/genetics , Autistic Disorder/physiopathology , Brain/physiopathology , Central Nervous System/drug effects , Cerebrovascular Circulation , Child , Delivery of Health Care, Integrated/standards , Developmental Disabilities/diagnosis , Humans , Immune System/drug effects , Liver/drug effects , Liver/physiopathology , Xenobiotics/adverse effects , Xenobiotics/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...